Windy City Media Group Frontpage News
Celebrating 30 Years of Gay Lesbian Bisexual and Trans News
home search facebook twitter join
Gay News Sponsor Windy City Times 2015-09-30
About WCMG Publications News Index  Entertainment Features Bars & Clubs Calendar Videos Advertisers OUT! Guide    Marriage


AIDS confab opens with news of HIV+ baby's "cure"
by Bob Roehr

facebook twitter pin it stumble upon digg google +1 reddit email

A flurry of excitement over a claimed "functional cure" for HIV opened the 20th Conference on Retroviruses and Opportunistic Infections (CROI) here in Atlanta. But questions remain about some of the details of what happened with the young girl, and even if it proves to be true, it is likely to have little immediate or widespread effect in daily care.

The case study involved a girl born prematurely at the University of Mississippi to a mother who was infected with HIV but did not know it. Because the mother had a high viral load at the time of delivery, and likelihood of transmission of the virus increases as viral load increases, the physician decided to test the infant for HIV and started her within 30 hours of birth on combination therapy.

The viral load test came back showing 20,000 copies of HIV. That strongly suggests she became infected in the womb and not at delivery, which is another point of high risk for mother to child transmission. While the RNA test for the virus showed that it was replication competent, there was no reason at the time to run a test used only in research and not in clinical practice to show if the virus was capable of infecting cells. A significant portion of HIV RNA has defects that leaves it incapable of infecting cells.

The infant remained on antiretroviral drugs for 18 months and then mother and daughter stopped going to clinic. They reappeared four months later and the girl had not been on therapy for much of that time. The doctors took a blood sample to measure her viral load but it was below the 20 copy level that they used.

That is when researchers from Johns Hopkins University stepped in. They used ultrasensitive tests to look for the virus but could not find it the first or subsequent times that they looked. "We were unable to detect replication competent virus," said lead author of the study Deborah Persaud. "We believe that perhaps the initiation of very early antiretroviral therapy prevented the formation of viral reservoirs in CD4 t-cells."

The child is two-and-a half years old now and apparently free from infection.

But questions remain. Was the initial viral load test accurate or was there some mix up in processing or record keeping? And was the virus capable of infecting cells? There is no stored blood sample so there is no way to answer those questions definitely.

"The question is whether the HIV DNA [detected by the study] is junk DNA or replication competent DNA." said Scott Hammer a researcher a Columbia University and vice chair of the conference. "Or is this an example of an elite controller and the baby would have cleared the virus without drugs."

Elite controllers are less than 1% of those who become infected. Their immune system has one or more unusual variations that are capable of controlling HIV infection for long periods of time, up to several decades, at very low levels and without clinical symptoms of disease.

There was much initial skepticism around the first person cured of AIDS, Timothy Ray Brown, first known only as the "Berlin patient." He underwent chemotherapy for lymphoma and a bone marrow transplant to rebuild his immune system. The doctor secured a transplant match that contained a rare variation — the delta32 mutation for the CCR5 cell receptor — known to naturally confer resistance to HIV infection. It took several years of monitoring for people to become convinced that Brown had been cured.

Even if this child does prove to be cured, the immediate impact on care for people will be small because most pregnant women receive care for their HIV to prevent transmission of the virus to their child. Fewer than 50 infants a year in the US acquire HIV infection around the time of birth, said Kevin Robert Frost, who heads up amfAR (American Foundation for AIDS Research). The shortfall is not in the science but in the delivery of care.

The same can be said of mother to child transmission of HIV in the rest of the world. The tools are there to virtually eliminate such transmission; often what is lacking is the healthcare infrastructure and the political will to implement those programs.


The news was less encouraging when it comes to using pills or microbicide gels to prevent the acquisition of HIV by women. The VOICE study enrolled 5029 primarily young single women in Africa. The complex trial had five groups and participants received either a vaginal microbicide gel containing tenofovir that was to be applied a short time prior to having sex, a daily pill of tenofovir, or Truvada, which contains tenofovir and another antiretroviral drug, or a placebo version of the gel or pill.

The gel groups in the study were stopped early when it became apparent that it would not offer any protection. The other groups continued to the end of the study, but neither of the pills proved to be protective. Tenoforvir pills had proven effective in some earlier PrEP (pre-exposure prophylaxis) studies.

"None of the products were efficacious in preventing HIV acquisition in women," said Jeanne Marrazzo, a researcher from the University of Washington who participated in the study. When they looked at stored samples to measure drug concentrations in the blood, only about 30% were using the products frequently enough to be detected in their blood. "The bottom line is that the women were not using the product."

Stigma around HIV medications appears to be a major reason why the young women were not taking the drug, she said. Others have suggested that perhaps the women were giving or selling the drug to people who were already infected.

"A long acting product would be great because it reduces the barrier to having to do something every day, if women want that product," according to Marrazzo. The monthly birth control injection Depo-Provera is popular with some women because it provides discretion that a pill might not offer, added Sharon Hillier, a leading HIV prevention researcher at the University of Pittsburgh. It would be good to develop a similar long-lasting option for HIV prevention.

facebook twitter pin it stumble upon digg google +1 reddit email

Windy City Media Group does not approve or necessarily agree with the views posted below.
Please do not post letters to the editor here. Please also be civil in your dialogue.
If you need to be mean, just know that the longer you stay on this page, the more you help us.


PrEP forum examines getting more physicians on board 2015-10-04
GMHC welcomes W.H.O.'s guidelines on antiretroviral therapy and PrEP 2015-09-30
HIV/AIDS Advocates: PrEP controversy makes job difficult 2015-09-30
Performance artist Karen Finley talks AIDS, pope, Planned Parenthood 2015-09-30
Tammy Baldwin introduces bill to enhance access to HIV/AIDS care 2015-09-29
Lambda launches "Know Your Rights" hub for people living with HIV 2015-09-29
Thousands at Chicago AIDS Run & Walk 2015-09-26
Upcoming: AIDS Run & Walk; Branden James; a-ha; Halloween 2015-09-23
Season of Concern celebrates Biscotto-Miller Fund's 30th 2015-09-23
Dancing for Life 2015-09-23
Sloan to step down from Chicago House post in 2016 2015-09-16
Positively Aware and TPAN call for all to participate in A Day with HIV 2015-09-12
Open Door observes National HIV/AIDS and aging awareness day 2015-09-11
Windy City Times survey of LGBT and AIDS organizations 2015-09-09
Upcoming in sports: AIDS Run & Walk; Chicago Sky; Race Judicata 2015-09-09
Protesters call on Kirk, Durbin to commit to HIV/AIDS support 2015-09-06
AIDS organization changes name for 'broadening' mission 2015-09-06
Sex workers, allies rally against Rentboy raids 2015-09-06
'Transformations' event looks at HIV within trans demo 2015-09-02
AIDS Run & Walk Chicago continues to expand 2015-09-02
No new infections in large-scale PrEP study 2015-09-02
Upcoming events in sports 2015-09-02
HIV/AIDS funding rally Sept. 4 2015-09-01
Study: Multiple barriers to HIV testing for teens 2015-09-01
Chicago HIV/AIDS funding rally Sept. 4 2015-09-01
Homeland Security raids offices in New York 2015-08-26
NIH: Research at crucial point in AIDS pandemic 2015-08-20
Conference to look at HIV and the trans community 2015-08-19
AIDS Legal Council holds annual summer benefit 2015-08-18
Proud to Run presents $40,000 to community beneficiaries 2015-08-12
Sports briefs: Kickball registration; AIDS Run & Walk; Rodeo 2015-08-12
Conference to look at HIV and the trans community 2015-08-10
Peller, Rice-Minoso honorary grand marshals 2015-08-09
Survey to assess needs, realities of transgender people with HIV/AIDS 2015-08-06
Chicago groups get $3.8M CDC grant for HIV targeted testing program 2015-08-05
SPORTS AIDS Run & Walk; XS Tennis, Lacoste partner 2015-08-05
Webinar discusses latest issues involving women and PrEP 2015-08-04
New amfAR report lists state priorities for national HIV/AIDS goals 2015-08-02
White House updates federal HIV/AIDS strategies 2015-07-30
New AFC initiative focuses on women of color 2015-07-29

Copyright © 2015 Windy City Media Group. All rights reserved.
Reprint by permission only. PDFs for back issues are downloadable from
our online archives. Single copies of back issues in print form are
available for $4 per issue, older than one month for $6 if available,
by check to the mailing address listed below.

Return postage must accompany all manuscripts, drawings, and
photographs submitted if they are to be returned, and no
responsibility may be assumed for unsolicited materials.
All rights to letters, art and photos sent to Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago
Gay and Lesbian News and Feature Publication) will be treated
as unconditionally assigned for publication purposes and as such,
subject to editing and comment. The opinions expressed by the
columnists, cartoonists, letter writers, and commentators are
their own and do not necessarily reflect the position of Nightspots
(Chicago GLBT Nightlife News) and Windy City Times (a Chicago Gay,
Lesbian, Bisexual and Transegender News and Feature Publication).

The appearance of a name, image or photo of a person or group in
Nightspots (Chicago GLBT Nightlife News) and Windy City Times
(a Chicago Gay, Lesbian, Bisexual and Transgender News and Feature
Publication) does not indicate the sexual orientation of such
individuals or groups. While we encourage readers to support the
advertisers who make this newspaper possible, Nightspots (Chicago
GLBT Nightlife News) and Windy City Times (a Chicago Gay, Lesbian
News and Feature Publication) cannot accept responsibility for
any advertising claims or promotions.








About WCMG Publications News Index  Entertainment Features Bars & Clubs Calendar Videos Advertisers OUT! Guide    Marriage

About WCMG      Contact Us      Online Front  Page      Windy City  Times      Nightspots      OUT! Guide     
Identity      BLACKlines      En La Vida      Archives      Subscriptions      Distribution      Windy City Queercast     
Queercast Archives      Advertising  Rates      Deadlines      Advanced Search     
Press  Releases      Event Photos      Join WCMG  Email List      Email Blast     
Upcoming Events      Todays Events      Ongoing Events      Post an Event      Bar Guide      Community Groups      In Memoriam      Outguide Categories      Outguide Advertisers      Search Outguide      Travel      Dining Out      Blogs      Spotlight  Video     
Classifieds      Real Estate      Place a  Classified     

Windy City Media Group produces Windy City Queercast, & publishes Windy City Times,
The Weekly Voice of the Gay, Lesbian, Bisexual and Trans Community,
Nightspots, Out! Resource Guide, and Identity.
5315 N. Clark St. #192, Chicago, IL 60640-2113 • PH (773) 871-7610 • FAX (773) 871-7609.